Cargando…

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C virus (HCV) treatment landscape in the last 4 years, providing cure rates over 95% with a shorter duration of treatment and a very good safety profile. This has enabled access to treatment in nearly al...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourlière, Marc, Pietri, Olivia, Castellani, Paul, Oules, Valérie, Adhoute, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295690/
https://www.ncbi.nlm.nih.gov/pubmed/30574189
http://dx.doi.org/10.1177/1756284818812358